Zydus and Synthon partner to launch Ozanimod in the U.S., targeting multiple sclerosis with shared regulatory and commercial responsibilities.

• Synthon files ANDA for Ozanimod, responsible for final FDA approval, manufacturing, and supply, enabling 180-day exclusivity upon launch.
• Zydus will handle U.S. commercialization, expanding patient access to essential medicines in multiple sclerosis and ulcerative colitis treatment.
• Ozanimod U.S. market estimated at $637 million; collaboration reinforces both companies’ focus on innovative, complex generic and specialty therapies.